Cargando…

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

AIMS: A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient‐specific and concurrent medication factors on pevonedistat PK. METHODS: Data were pooled from 6 clinical studies consisting of 335 patients with solid tumours or haematological malignancies administered...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faessel, Hélène M., Mould, Diane R., Zhou, Xiaofei, Faller, Douglas V., Sedarati, Farhad, Venkatakrishnan, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848912/ https://www.ncbi.nlm.nih.gov/pubmed/31355467 http://dx.doi.org/10.1111/bcp.14078

Ejemplares similares

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial
por: Zhou, Xiaofei, et al.
Publicado: (2021)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
por: Handa, Hiroshi, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
por: Swords, R T, et al.
Publicado: (2017)

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
por: Suri, Ajit, et al.
Publicado: (2020)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Cancer Chemotherapy—Its role in the Treatment Strategy of Haematologic Malignancies and Solid Tumours
por: Crowther, D.
Publicado: (1977)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Targeting hypoxia in solid and haematological malignancies
por: Harris, Bill, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study
por: Suri, Ajit, et al.
Publicado: (2019)

Comparison of epidemiological, clinical and microbiological characteristics of bloodstream infection in children with solid tumours and haematological malignancies
por: Garrido, M. M., et al.
Publicado: (2019)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Cytomegalovirus in Haematological Tumours
por: Alonso-Álvarez, Sara, et al.
Publicado: (2021)

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey
por: Lebret, T., et al.
Publicado: (2016)

The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours
por: Yilmaz, Bahiddin, et al.
Publicado: (2016)

Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.
por: Fridborg, H., et al.
Publicado: (1994)

Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours
por: Greaves, David, et al.
Publicado: (2022)

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018)

Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway
por: Xu, Junfeng, et al.
Publicado: (2022)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies
por: Mosaad, Manar, et al.
Publicado: (2021)

Standard haematology practice/2 /
Publicado: (1994)

Hæmatological Standards: Edinburgh 1949
por: Hendry, Edward B.
Publicado: (1949)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
por: Voss, Martin H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vtul5trqki2fs7ijduvseevgsc